Robert Mannel to Quinazolines
This is a "connection" page, showing publications Robert Mannel has written about Quinazolines.
Connection Strength
0.655
-
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009 Jul; 19(5):929-33.
Score: 0.328
-
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):507-12.
Score: 0.125
-
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun; 129(3):486-94.
Score: 0.106
-
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2012 Mar; 124(3):569-74.
Score: 0.096